Astrocytes are the most abundant cells in the CNS. Under normal conditions, astrocytes modulate synaptic activity and provide nutrients and support for neuronal survival [1] [2] [3] [4] . In the context of neuroinflammation, astrocytes control infiltration of peripheral proinflammatory leukocytes into the CNS [5] [6] [7] [8] , and it has been suggested that they regulate the activity of microglia, oligodendrocytes and cells of the adaptive immune system 9 . Thus, it is important to characterize the mechanisms regulating astrocyte activation during CNS inflammation, as well as potential targets for the therapeutic modulation of astrocyte activity.
Astrocytes are the most abundant cells in the CNS. Under normal conditions, astrocytes modulate synaptic activity and provide nutrients and support for neuronal survival [1] [2] [3] [4] . In the context of neuroinflammation, astrocytes control infiltration of peripheral proinflammatory leukocytes into the CNS [5] [6] [7] [8] , and it has been suggested that they regulate the activity of microglia, oligodendrocytes and cells of the adaptive immune system 9 . Thus, it is important to characterize the mechanisms regulating astrocyte activation during CNS inflammation, as well as potential targets for the therapeutic modulation of astrocyte activity.
MS is a chronic demyelinating autoimmune disease of the CNS. In most patients, MS initially presents a relapsing-remitting clinical course (relapsing-remitting MS) that is followed by a progressive phase (secondary progressive MS (SPMS)) characterized by a continued and irreversible accumulation of disability, in which available treatments show limited efficacy 10 . Recent findings suggest that the local CNS innate immune response drives disease progression in SPMS 9, 11, 12 . Thus, we investigated the role of astrocytes in CNS autoimmunity using a mouse experimental model that recapitulates several aspects of SPMS.
Here we report that LacCer, produced by the enzyme B4GALT6 in astrocytes during chronic CNS inflammation, acts in an autocrine manner to promote inflammation and neurodegeneration. We also found high expression of B4GALT6 and high LacCer concentrations in CNS lesions from individuals with MS. These findings identify B4GALT6 in astrocytes as a driver of chronic CNS inflammation and as a potential therapeutic target for the treatment of MS and other neuroinflammatory disorders.
RESULTS
LacCer synthases control autoimmune CNS inflammation EAE constitutes a useful experimental model of MS, but different aspects of the disease are modeled in different mouse strains. C57BL/6 mice immunized with a peptide encoded the region between amino acids 35 and 55 of myelin oligodendrocyte glycoprotein (MOG ) develop a monophasic EAE that resembles a single attack during relapsing-remitting MS. Immunization of nonobese diabetic (NOD) mice with MOG , however, results in an acute attack (acute phase) followed by a phase of progressive and irreversible accumulation of neurological impairment (progressive phase) that resembles SPMS 13, 14 .
We found that F1 hybrid mice derived from breeding NOD mice with C57BL/6 mice develop a chronic progressive form of EAE ( Supplementary Fig. 1 ). To study the role of astrocytes during CNS inflammation, we analyzed the course of EAE in F1 NOD C57BL/6 glial fibrillary acidic protein-herpes simplex virus thymidine kinase (GFAP-HSV-TK) hybrid mice, in which reactive astrocytes can be depleted by ganciclovir (GCV) administration ( Supplementary  Fig. 2a ). In accordance with previous findings in C57BL/6 mice 7, 8 , the depletion of reactive astrocytes during the acute phase of EAE 1 1 4 8 VOLUME 20 | NUMBER 10 | OCTOBER 2014 nature medicine resulted in worse clinical scores (Fig. 1a) . However, astrocyte depletion during the progressive phase led to decreased clinical scores (Fig. 1a) . Moreover, although reactive astrocyte depletion in acute EAE results in increased monocyte and T cell recruitment to the CNS 5, 8 , compared to control mice; depletion during the progressive phase of EAE decreased leukocyte infiltration into the CNS (Supplementary Fig. 2b ) but did not affect the peripheral T cell response ( Supplementary Fig. 2c,d ). Of note, although GCV and linear regression curves (right) in F1 NOD C57BL/6 wild-type (WT) and F1 NOD C57BL/6 GFAP-HSV-TK mice transgenic (GFAP TK ) F1 hybrid mice (mean ± s.e.m.) treated with GCV (green bar) or vehicle (PBS) during the acute (top) or progressive phase of EAE (bottom). Thin lines (right) indicate 95% confidence interval of the regression line. Representative data from one of three independent experiments with n = 7 WT and 9 (GFAP TK ) mice. (b) Left, heatmap of differential mRNA expression profiles in astrocytes isolated from the CNS of naive NOD mice or during the acute or progressive phase of NOD EAE; representative data of one of three independent experiments. Right, heatmap depicting a unique gene cluster specifically upregulated during the progressive phase of EAE. (c) qPCR analysis of B4galt6 expression in microglia and astrocytes from naive or EAE NOD mice, normalized to Gapdh and presented relative to that in cells from naive mice. Representative data of three independent experiments; Student's t-test. (d) Quantification of LacCer in the CNS of naive or EAE NOD mice, relative to net tissue weight. Representative data (mean and s.e.m.) of three independent experiments; n = 15 (naive and acute) or 20 (chronic) samples per condition; Student's t-test. (e) EAE clinical scores (left) and regression curves (right) in C57BL/6 (e) and NOD (f) mice after administration of LacCer or vehicle and MOG during the acute EAE phase (e) or of LacCer or vehicle only during the progressive phase (f). Representative data of two independent experiments with n = 8 (vehicle) or 10 (LacCer) mice per group. Statistical analysis as in a. 
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administration potentially depletes neural progenitor cells in NOD C57BL/6 GFAP-HSV-TK hybrid mice, these cells show protective effects in EAE 15, 16 . Thus, these data suggest that depletion of reactive astrocytes is responsible for the amelioration of EAE.
To study the regulation of astrocyte activity, we isolated astrocytes from naive NOD mice or from EAE-induced NOD (NOD EAE) mice during the acute and the progressive phases of EAE ( Supplementary  Fig. 3 ) and analyzed their transcriptomes with NanoString nCounter arrays (Supplementary Table 1) . We detected mRNA expression profiles linked to different stages of NOD EAE and identified a set of genes upregulated during the progressive phase (Fig. 1b) . One of the genes whose expression was associated with progressive NOD EAE was B4galt6, encoding a LacCer synthase 17 . B4galt6 upregulation in astrocytes, but not microglia, was validated by quantitative PCR (qPCR) (Fig. 1c) . Further validation by immunofluorescence detected B4GALT6 expression in white-matter astrocytes expressing glial fibrillary acidic protein (GFAP + ), but not in gray matter, perivascular glia limitans or nestin + neural progenitors ( Supplementary Fig. 4a,b) .
We also detected upregulation of β-1,4-galactosyltransferase 5 (B4GALT5); B4GALT5 and B4GALT6 are the only members of the B4GALT family with LacCer synthase activity 17 ( Supplementary Fig. 4c ). Indeed, in agreement with the LacCer synthase activity of B4GALT5 and B4GALT6 (B4GALT5/6), we detected increased LacCer levels in the CNS during the progressive phase of NOD EAE (Fig. 1d) .
We then investigated the effects of LacCer on CNS inflammation. LacCer administration worsened EAE in C57BL/6 and NOD mice ( Fig. 1e,f ) but could not induce EAE or astrocyte activation in vivo in the absence of MOG Fig. 5a ). Of note, LacCer administration did not affect the T cell response ( Supplementary  Fig. 5b-e) .
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To further investigate the role of LacCer in the progressive phase of NOD EAE, we inhibited its synthesis using the B4GALT5/6-specific inhibitor d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) 17 (Fig. 1g) . Daily PDMP administration initiated 40 d after the induction of EAE lowered CNS LacCer levels ( Fig. 1h ) and suppressed disease progression as evaluated by clinical score, demyelination and axonal loss (Fig. 1i,j) . PDMP did not affect the T cell response ( Supplementary Fig. 5f-i) . Taken together, these data suggest that LacCer produced by B4GALT5/6 exacerbates CNS inflammation.
B4GALT5/6 inhibition suppresses astrocyte activation in EAE
LacCer has been suggested to promote pathology during experimental spinal cord injury 18 . We studied the effects of B4GALT5/6 inhibition on the transcriptional program of astrocytes isolated from vehicle-or PDMP-treated NOD mice during the progressive phase of EAE (day 100 after disease induction). Our unbiased analysis identified two sets of genes: those downregulated during EAE and upregulated by PDMP (cluster 1), and those upregulated during EAE and downregulated by PDMP (cluster 2) (Fig. 2a) . Cluster 2 included several genes associated with EAE and MS pathology: Ccl2 (involved in recruitment of and B4galt6 expression in naive mice or in EAE NOD mice after injection with astrocyte-specific shControl, shB4galt5 or shB4galt6 lentivirus at day 35 after EAE induction. n = 10 mice per group; expression normalized to Gapdh and presented relative to that of cells from naive mice. Representative data of two independent experiments; one-way ANOVA followed by Tukey post hoc analysis. (f,g) LacCer abundance (f) and EAE clinical scores (g) in the CNS of naive or EAE NOD mice as in Figure 1a ; statistical analysis by one-way ANOVA followed by Tukey post hoc analysis (f) or as in Figure 1a (also known as Opn, encoding osteopontin), Nos2 (encoding nitric oxide synthase), H2-Aa (encoding major histocompatibility complex class II) and Vim (encoding vimentin). The suppressive effects of PDMP on the expression of representative genes included in cluster 2 were validated by qPCR (Fig. 2b) . Additional support for the role of B4GALT6 in regulating the expression of genes associated with CNS pathology was provided by the coexpression of B4GALT6 with CCL2 and inducible nitric oxide synthase (iNOS) in GFAP + astrocytes (Supplementary Fig. 6 ). Moreover, because astrocytes regulate de-and re-myelination 9,22 , we analyzed the expression of genes linked to the control of these processes by astrocytes (Supplementary Table 2 and Fig. 2c ). B4GALT5/6 inhibition by PDMP reduced the expression of demyelination-associated genes and increased the expression of remyelination-associated genes (Fig. 2c) . Collectively, these data demonstrate that B4GALT5/6 controls astrocyte activation during EAE.
To identify the molecular mechanisms mediating the effects of B4GALT5/6 blockade on the transcriptional response of astrocytes during EAE, we searched the promoter sequence of the genes included in clusters 1 and 2 for the enrichment of specific transcription factor binding sites. We found that genes included in cluster 2, whose expression was suppressed by B4GALT5/6 inhibition, were enriched for interferon-sensitive response elements (ISREs) (P = 4.83 × 10 −6 ) and nuclear factor-κB (NF-κB) response elements (P = 9.99 × 10 −6 ). (P values determined by the PRIMA algorithm; see Online Methods). Indeed, expression of Irf1 (encoding interferon regulatory factor 1 (IRF-1)) and RelB (encoding RELB, a sub-unit of the NF-κB complex) was upregulated during EAE and downregulated by PDMP treatment (Fig. 2d,e) . These results suggest that B4GALT5/6 controls NF-κB and IRF-1 activation during CNS inflammation. Statistical analysis by two-way ANOVA showed no significance effect of the LacCer or PDMP treatments on monocyte migration. All data presented as mean and s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. LacCer produced by B4GALT6 promotes astrocyte activation To investigate whether LacCer produced by B4GALT5/6 acts directly on astrocytes to regulate their activity, we studied the effects of B4GALT5/6 inhibition and LacCer supplementation on the transcriptional response of primary astrocytes to activation. B4GALT5/6 inhibition with PDMP suppressed the response of astrocytes to stimulation npg with lipopolysaccharide and interferon-γ (LPS/IFN-γ) ( Fig. 3a and  Supplementary Fig. 7a) . Conversely, supplementation with exogenous LacCer boosted the astrocyte response to LPS/IFN-γ, suggesting that LacCer synthesized by B4GALT5/6 acts in an autocrine manner to promote astrocyte activation ( Fig. 3a and Supplementary Fig. 7a) . Consistent with this, exogenous LacCer overcame the suppressive effects of PDMP on astrocyte activation (Fig. 3a and Supplementary  Fig. 7a ). Similar effects of PDMP and LacCer were found in astrocytes activated with IL-1β, poly(I:C), or IFN-γ and interleukin-17 (data not shown). Notably, PDMP or LacCer treatment did not affect astrocyte viability (Supplementary Fig. 7b,c) .
To analyze the relative contributions of B4GALT5 and B4GALT6 on astrocyte activation 17, 23, 24 , we knocked down B4galt5 and B4galt6 expression using lentivirus-delivered small hairpin RNAs (shRNAs) (Fig. 3b) . The knockdown of B4galt6 suppressed the upregulation of H2-Aa, Ccl5 and Cxcl10 triggered by LPS/IFN-γ activation to a similar extent as did PDMP treatment. However, the knockdown of B4galt5 did not have a significant effect (Fig. 3c) , suggesting that B4GALT6 has a dominant role in astrocyte activation. Of note, in astrocytes in which B4galt6 had been knocked down with shRNA, PDMP treatment did not further suppress H2-Aa, Ccl5 and Cxcl10 expression, suggesting that the effects of PDMP result from the specific inhibition of B4GALT6-dependent LacCer synthesis (Supplementary Fig. 7d) .
To determine the relative contribution of B4GALT5 and B4GALT6 on EAE progression, we used a lentivirus-based system optimized for astrocyte-specific knockdown in vivo 25 (Fig. 3d) . In this system, the Gfap promoter drives the expression of an shRNA of choice and a GFP reporter. After intracerebroventricular (i.c.v.) injection of shRNAencoding lentivirus during the progressive phase of NOD EAE, the GFP reporter was expressed in GFAP + astrocytes but not ionized calcium-binding adaptor molecule 1 (Iba1) + microglia and inflammatory macrophages (Fig. 3e and Supplementary Fig. 7e ). Consequently, we detected an astrocyte-specific knockdown of B4galt6 and B4galt5 expression (Fig. 3e) . The knockdown of B4galt6, but not of B4galt5, decreased the concentration of LacCer in the CNS during the progressive phase of NOD EAE (Fig. 3f) . Moreover, the knockdown of B4galt6, but not of B4galt5, suppressed disease progression in NOD mice (Fig. 3g) , suggesting that LacCer produced by B4GALT6 acts in an autocrine manner to promote astrocyte activation and EAE progression.
To study the molecular mechanisms mediating the effects of LacCer, we searched the promoters of genes regulated by LacCer in primary astrocytes in culture for specific transcription factor binding sites and detected significant enrichment (P < 10 −5 ) (P values determined by the PRIMA algorithm; see Online Methods) in NF-κB and ISRE responsive elements.
LacCer activates NF-kB in astrocytes 18, 26 , and we confirmed these observations on astrocytes in vitro (Supplementary Fig. 7f ). The role of IRF-1 and ISRE in the regulation of astrocyte activity by LacCer, however, is unknown. We found that LacCer treatment enhanced the translocation of IRF-1 to the nucleus in response to LPS/IFN-γ stimulation, whereas B4GALT6 inhibition interfered with this process (Fig. 3h) . Moreover, we detected the recruitment of NF-κB and IRF-1 to the Nos2 promoter in astrocytes activated with LPS/IFN-γ (Fig. 3i) . To study the functional role of IRF-1 on the response to LacCer, we evaluated the responses of wild-type and IRF-1-deficient astrocytes to activation with LPS/IFN-γ. IRF-1 deficiency abrogated the LacCer-mediated upregulation of Nos2 and other genes that harbor ISRE biding sites in their promoters (Csf2 (encoding granulocyte-macrophage colony-stimulating factor (GM-CSF)), Ccl2, Ccl5, Il6 and Tlr2) (Fig. 3j) . Moreover, IRF-1 was coexpressed with the chemokine CCL2 and iNOS in GFAP + astrocytes during progressive NOD EAE (Supplementary Fig. 7g) . Hence, LacCer produced by B4GALT6 controls astrocyte activity through pathways dependent on NF-κB and IRF-1.
The B4GALT6-LacCer axis regulates Ccl2 transcription in astrocytes Inflammatory monocytes recruited to the CNS by CCL2 promote neurodegeneration and disease progression in MS and EAE [19] [20] [21] 27 . On the basis of the effects of LacCer on Ccl2 expression and NF-κB and IRF-1 activation in astrocytes, we searched the Ccl2 promoter for responsive elements to these transcription factors and identified potential binding sites (Fig. 4a) . In reporter assays we found that IRF-1 and the NF-κB subunit p65 transactivate the Ccl2 promoter (Fig. 4b) . Moreover, we detected a significant recruitment of NF-κB and IRF-1 to the Ccl2 promoter in astrocytes activated with LPS/IFN-γ (Fig. 4c) . This recruitment was inhibited by PDMP, and the effects of PDMP were abrogated by the addition of exogenous LacCer (Fig. 4c) . Thus, LacCer produced by B4GALT6 controls Ccl2 expression.
To investigate the regulation of Ccl2 expression by LacCer in vivo, we analyzed the effect of B4GALT6 inhibition or knockdown on inflammatory monocyte recruitment to the CNS during NOD EAE. B4GALT6 inhibition by PDMP or knockdown of B4GALT6 knockdown in astrocytes by lentivirus-delivered shRNAs reduced the recruitment of inflammatory monocytes to the CNS (Fig. 4d,e) . PDMP or LacCer did not affect the viability of purified Ly6C high inflammatory monocytes, their migration in a CCL2 gradient, or their response to LPS/IFN-γ stimulation (Fig. 4f-i) . Thus, B4GALT6 in astrocytes controls CCL2 production and the recruitment of inflammatory monocytes into the CNS.
Non-cell-autonomous effects of B4GALT6 on microglial activation Microglia have a central role in CNS inflammation 28 . To study the effects of B4GALT5/6 on microglia, we analyzed their transcriptional profile by NanoString nCounter in naive mice, or during the progressive phase of NOD EAE in vehicle-or PDMP-treated mice. We found that B4GALT5/6 inhibition lowered the expression of genes associated with microglial activation during EAE (Fig. 5a,b) . Moreover, B4GALT5/6 inhibition led to the downregulation of genes linked to a proinflammatory (M1) phenotype and upregulation of genes associated with an anti-inflammatory (M2) phenotype in microglia and CNS-infiltrating monocytes (Fig. 5c and Supplementary Table 3) . Thus, although B4GALT5 and B4GALT6 are not upregulated by microglia during EAE, astrocyte-derived LacCer modulates the activation of microglia and CNS-infiltrating monocytes.
Given that B4GALT5/6 inhibition in vivo altered the expression of M1-and M2-associated genes in microglia and CNS-infiltrating monocytes (Fig. 5c) , we studied whether this effect was cell autonomous. We found that neither the viability nor the response of primary mouse microglia to LPS/IFN-γ was affected by B4GALT5/6 inhibition or the addition of LacCer in the absence of astrocytes (Fig. 5d,e and Supplementary Fig. 8a,b) . LacCer did not affect the transcriptional response to activation of leptomeningeal phagocytes or choroid plexus cells (Supplementary Fig. 8c,d) .
However, we detected significant effects of PDMP and LacCer on microglial activation in mixed glial cultures containing both microglia and astrocytes (Fig. 5f) . To identify the B4GALT6 and LacCerdependent mechanisms involved in the regulation of microglial activation by astrocytes, we used blocking antibodies. We treated mixed glial cultures with blocking antibodies to neutralize GM-CSF, IL-12, tumor necrosis factor-α (TNF-α) or IL-6 signaling and analyzed microglial activation (as indicated by nos2 upregulation) in the presence of LPS and IFN-γ and LacCer. We found that blockade of GM-CSF inhibited the LacCer-dependent increase in microglial Nos2 expression (Fig. 5g) . Moreover, the B4GALT6/LacCer pathway controlled NF-κB and IRF-1 recruitment to the Csf2 promoter during astrocyte activation (Fig. 5h) .
To evaluate the physiological relevance of these findings, we analyzed Csf2 expression in astrocytes after B4galt6 knockdown with shRNAs during the chronic phase of NOD EAE. In agreement with our in vitro results, B4galt6 knockdown lowered Csf2 expression in astrocytes during NOD EAE compared to controls (Fig. 5i) , concomitant with lowered Nos2 expression in microglia (Fig. 5j) . Taken together, these data suggest that GM-CSF produced by astrocytes in a B4GALT6-LacCer-dependent manner modulates microglia activation.
B4GALT6 and LacCer are upregulated in MS lesions
To examine the clinical relevance of our findings, we analyzed B4GALT6 and B4GALT5 expression by qPCR in brain samples from patients with MS and from healthy controls. We found higher expression of B4GALT5 (2.15 ± 0.28-fold) and B4GALT6 (8.26 ± 2.11-fold) compared to controls in MS lesions but not in normal-appearing white matter (NAWM) or controls (Fig. 6a) . We also detected coexpression of B4GALT6 with CCL2 and iNOS in GFAP + astrocytes in individuals with MS (Fig. 6b) . The high expression of B4GALT5/6 was associated with high LacCer levels in MS lesions (Fig. 6c) , suggesting that high B4GALT6 activity and LacCer levels are also linked to MS pathology.
We next studied whether B4GALT6 modulates the activity of primary human astrocytes activated with the Toll-like receptor 3 (TLR-3) agonist poly(I:C) or interleukin 1β (IL-1β). We found that B4GALT6 inhibition led to a significant decrease in CCL2, CCL5, COX2, IL6, NOS2 and TLR2 mRNA expression as measured by qPCR (Fig. 6d) . These results suggest that B4GALT6 is a potential therapeutic target for the regulation of astrocyte activity in human neuroinflammatory disorders. DISCUSSION GFAP high reactive astrocytes modulate leukocyte infiltration 7, 8 and regulate the inflammatory response 5-9 after CNS trauma and in acute EAE, but their regulation and function during chronic CNS inflammation is poorly understood. We found that B4GALT6 in astrocytes promotes astrocyte activation and neuroinflammation during chronic EAE. B4GALT5 and B4GALT6 are the only members of the β4-galactosyltransferase family that catalyze LacCer synthesis 17 . Both enzymes are upregulated by astrocytes during chronic EAE and MS, but B4GALT6, and not B4GALT5, is responsible for the high CNS LacCer levels, astrocyte activation and disease progression. These findings are in line with previous studies that described different biological roles for B4GALT5 and B4GALT6, for example in embryonic development 23, 24 . Moreover, B4GALT6 deficiency results in reduced LacCer synthase activity in the CNS of naive mice; LacCer synthesis in the kidney, however, is controlled by B4GALT5 (ref. 24 ). Taken npg together, these data suggest a spatial and functional compartmentalization of B4GALT5 and B4GALT6 LacCer synthase activities.
Proinflammatory microglia and CNS-infiltrating monocytes, recruited and activated in response to factors present in the inflamed CNS microenvironment, are thought to contribute to the pathogenesis of MS and other neurodegenerative disorders [29] [30] [31] . We found that the LacCer synthesized by B4GALT6 in astrocytes controls the production of chemokines and cytokines, such as CCL2 (refs. 19-21,27 ) and GM-CSF 32 , that regulate recruitment and activation of inflammatory monocytes and microglia. The effects of LacCer on astrocytes involve IRF-1 and NF-κB, but although LacCer is reported to modulate protein kinase C and cytoplasmic phospholipase A2 signaling 33, 34 and membrane microdomains 17 , the mechanisms by which LacCer controls these transcription factors are not completely understood.
Lipids exert pronounced effects on inflammation in the context of autoimmunity and microbial infections, acting either as targets or regulators of the immune response 14, [35] [36] [37] [38] [39] [40] . Although lipid-specific antibodies and T cells have been identified in MS 37, 39 , the role of bioactive lipids in CNS autoimmunity is mostly unknown. Myelin sheath lipids have been reported to induce apoptosis in autoreactive T cells and ameliorate EAE 35 . Considering the proinflammatory effects of LacCer, it seems that perturbations in the balance of antiand proinflammatory lipids in the CNS have an important role in MS pathology. Thus, comprehensive profiling of CNS lipids is likely to identify new targets for therapeutic intervention in MS and also for other neurological disorders in which astrocyte activation contributes to disease pathology.
In conclusion, our results demonstrate that the B4GALT6-LacCer axis in astrocytes controls processes that drive CNS inflammation and neurodegeneration. Thus, the modulation of glycolipid synthesis is a potential therapeutic approach for MS and also for other neurologic disorders in which astrocyte activation contributes to disease pathology.
METHODS
Methods and any associated references are available in the online version of the paper. ultra-high purity. The internal standard LacCer (18:1/12:0) was dissolved in 2:1 chloroform-methanol (v/v), 6 ml of 2:1 chloroform-methanol and 2 ml of PBS. After approximately 2 min of homogenization, the liquid was transferred to an 8-ml glass vial. The mixture was spun in a high speed centrifuge at 1,000g for 20 min. This resulted in the formation of a protein disk and insoluble materials in the middle. The bottom layer was removed using a glass Pasteur pipet and transferred to a clean vial for evaporation under a stream of gentle nitrogen. The dried sample was reconstituted in 100 µl of 2:1 chloroform-methanol and analyzed using the HPLC-MS. nCounter gene expression. 100-200 ng of total RNA was hybridized with reporter and capture probes for nCounter Gene Expression code sets (Mouse Inflammation Kit, or a custom-made astrocyte-oriented probe set (Supplementary Table 1) ), according to manufacturer's instructions (NanoString Technologies). Data were normalized to spiked positive controls and housekeeping genes (nSolver Analysis system). Transcript counts less than the mean of the negative control transcripts +2 s.d. for each sample were considered background.
